免疫疗法用于新辅助治疗局部肾细胞癌患者的可行性
虽然肾细胞癌(RCC)的标准治疗方法不包括新辅助全身治疗,但理论上在肾切除术之前加入新辅助治疗有诸多好处:
1)癌细胞的减少允许了之前不适合手术的患者进行部分肾切除术或消融术,而肿瘤的分期降低也提高了之前患有局部晚期,无法切除的肾癌患者的手术可切除性。
2)早期的全身系统性治疗还可以减少微转移疾病的可能性并降低复发率。
3)对由于各种其他因素,如高血压,恶性心率失常,血液疾病等导致手术推迟的患者来说,新辅助治疗还起到了控制和治疗肿瘤的作用,为择期手术和综合治疗创造条件。
▼ Figure1:PROSPER RCC治疗方案
▼ Figure 2:NCT02210117治疗方案
1. Karam JA, et al.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cellcarcinoma. Eur Urol. 2014 Nov;66(5):874-80.
2. Zhang Y, Li Y, Deng J,Ji Z, Yu H, et al. (2015) Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal CellCarcinoma. PLOS ONE 10(2): e0115896.
3. Cai W, Huang J,Yuan Y, Hu X, Li M, Kong W, Zhang J, Guo J, Chen Y, Huang Y: Sunitinib or Sorafenib as Neoadjuvant Therapy May notImprove the Survival Outcomes of Renal Cell Carcinomawith Tumor Thrombus. Urol Int 2018;101:391-399.
4. Patel HD, GorinMA, Rowe SP, et al. Neoadjuvant nivolumab in patients with high-risk non-metastatic renal cell carcinoma.Presented at: 2020 SUO Annual Meeting; December 2-5, 2020; Virtual. Abstract 92.
5. Ornstein M, et. al.,A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC).J ClinOncol 38: 2020 (suppl; abstr 5021).
6. Gao J,Karam J, Tannir N, et.al.,A pilot randomized study evaluating nivolumab (nivo)or nivo + bevacizumab (bev) or nivo + ipilimumab(ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).J Clin Oncol 37:2019 (suppl; abstr 4501).
精彩推荐:
- End -